Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: GATT legislation

Executive Summary

GATT legislation: Sen. Hatch (R-Utah) pledges to begin hearings in the Judiciary Committee on pharmaceutical patent issues on Feb. 27, 1996 and hold a mark-up by the end of March, according to a Dec. 13 letter to Sen. Pryor (D-Ark.). Pryor's legislation, which would permit generic companies to market products during the extended patent period granted by GATT, was referred to the Judiciary Committee in a 49-48 vote when it was offered as an amendment to the partial-birth abortion ban bill the week of Dec. 8 ("The Pink Sheet" Dec. 11, T&G-7)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027386

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel